Acalabrutinib Regimens Improve PFS in Treatment-Na ïve Patients with CLL
Acalabrutinib alone and in combination with obinutuzumab significantly improved progression-free survival, compared with obinutuzumab plus chlorambucil in treatment-na ïve patients with chronic lymphocytic leukemia (Source: CancerNetwork)
Source: CancerNetwork - December 8, 2019 Category: Cancer & Oncology Authors: Gina Columbus Source Type: news
E1912 follow-up shows ibrutinib effective, well tolerated by majority of CLL patients
(ECOG-ACRIN Cancer Research Group) The ECOG-ACRIN Cancer Research Group today announced results from extended follow-up of patients in its randomized Phase 3 clinical trial, E1912. Previously untreated patients (aged 70 or younger) with chronic lymphocytic leukemia (CLL) who received ibrutinib-based therapy lived longer and with sustained benefit, compared to standard FCR chemoimmunotherapy. The updated analysis supports the earlier trial findings (Shanafelt, New England Journal of Medicine, August 2019). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 7, 2019 Category: International Medicine & Public Health Source Type: news
Fungal Infections in Chronic Lymphocytic Leukemia before and after Treatment
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - December 5, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Calquence Approved to Treat CLL, SLL
FRIDAY, Nov. 22, 2019 -- The U.S. Food and Drug Administration has granted supplemental approval to Calquence (acalabrutinib) for treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the agency announced... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 22, 2019 Category: General Medicine Source Type: news
Ohio State-developed drug receives FDA approval for treatment of CLL and SML
(Ohio State University Wexner Medical Center) On Nov. 21, 2019, the US Food and Drug Administration (FDA) approved the use of the drug acalabrutinib for first-line therapy in chronic lymphocytic leukemia and small cell lymphoma. This is the first full approval of the targeted drug therapy, which was developed and tested at The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, in collaboration with the pharmaceutical partner, Acerta Pharma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 22, 2019 Category: Cancer & Oncology Source Type: news
AstraZeneca gets FDA ok for lymphocytic leukemia drug
AstraZeneca announced that the U.S. FDA has approved Calquence for adult patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 21, 2019 Category: Pharmaceuticals Source Type: news
FDA Approves Calquence for Adults with Chronic Lymphocytic Leukemia
21 November 2019 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1 The... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 21, 2019 Category: Drugs & Pharmacology Source Type: news
FDA Approves Acalabrutinib to Treat CLL/SLL
As part of Project Orbis, The FDA has approved acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - November 21, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Supplemental New Drug Application -- submitted through FDA Real-Time Oncology Review program -- is based on positive Phase 3 data in patients aged 70 or younger
RARITAN, N.J., Nov. 8, 2019 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharma... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, Johnson & Johnson, IMBRUVICA, ibrutinib (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 8, 2019 Category: Pharmaceuticals Source Type: news
Risk for Second Primary Malignancy Up in CLL Survivors
FRIDAY, Nov. 1, 2019 -- Survivors of chronic lymphocytic leukemia (CLL) have an increased risk for second primary malignancy (SPM), according to a study published online Sept. 30 in Blood Cancer Journal.
Vivek Kumar, M.D., from Harvard Medical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 1, 2019 Category: Pharmaceuticals Source Type: news
PHARMAC funding venetoclax for chronic lymphocytic leukaemia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 31, 2019 Category: Drugs & Pharmacology Source Type: news
Risk of Infectious Complications in Patients with Chronic Lymphocytic Leukemia in the Era of BCR Inhibitors: A Retrospective Single Institution Experience
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 8, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Hypertension & CV Adverse Events With Ibrutinib in'Real World'Hypertension & CV Adverse Events With Ibrutinib in'Real World '
Ibrutinib has changed the treatment landscape of chronic lymphocytic leukemia, but emerging real-world data suggest caution, owing to hypertension and other CV adverse events.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 8, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Invasive Aspergillosis in Chronic Lymphocytic Leukemia: Therapy and Outcomes
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 6, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Chronic Lymphocytic Leukemia: 5 Things to Know Chronic Lymphocytic Leukemia: 5 Things to Know
The most common adult leukemia has seen a rush of new evidence in recent years. Here are some of the highlights.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 24, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news
